Genetic and Environmental Determinants of Triglycerides (GOLDN)

This study has been completed.
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
University of Alabama at Birmingham Identifier:
First received: May 21, 2004
Last updated: November 16, 2013
Last verified: November 2013
To characterize the genetic basis of the variable response of triglycerides to two environmental contexts, one that raises triglycerides (dietary fat), and one that lowers triglycerides (fenofibrate treatment.)

Cardiovascular Diseases
Heart Diseases

Study Type: Observational
Study Design: Time Perspective: Prospective

Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • describe the association between blood lipids and gene variants [ Time Frame: 3 weeks after start of fenofibrate intervention // 3 weeks after start of fenofibrate intervention ] [ Designated as safety issue: No ]
    Blood lipids were measured by the following: triglyceride, high-density cholesterol, low-density cholesterol concentrations. We will describe the association between blood lipids and gene variants.

Enrollment: 1327
Study Start Date: September 2002
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Detailed Description:


Hypertriglyceridemia is emerging as an important predictor of atherosclerosis, and recent evidence suggests related phenotypes of triglycerides (TGs), such as TG remnant particles and small lactate dehydrogenase (LDL) particles, are particularly atherogenic. There is considerable variation in the response of TGs and related phenotypes to the environment.

The study is in response to a Request for Applications (RFA) entitled " Interaction of Genes and Environment in Shaping Risk Factors for Heart, Lung, Blood, and Sleep Disorders". The RFA was released in October, 2001.


Measurements will be collected before and after a dietary fat challenge to assess postprandial TGs and related atherogenic phenotypes (VLDL TGs, chylomicron TGs, TG remnant particles, high-density lipoprotein(HDL) and low density lipids (LDL) particle sizes, total cholesterol, LDL-C, and HDL-C). In families with 2 or more members in a sibship with high TGs (>= 130 mg/dl), the authors will conduct a short-term, placebo-controlled, randomized trial of fenofibrate in all willing and eligible family members (anticipated sample size = 1,200). A two-period crossover design will be executed with a 2-week washout between two 3-week treatment periods (placebo or micronized fenofibrate, 160 mg). About 1,000 family members have a Marshfield genome marker set available as part of national Heart Lung and Blood (NHLBI) FHS; the remaining 1,400 will be typed using the same marker set. They will conduct genome-wide linkage analyses using state-of-the-art methods to localize novel genetic loci contributing to TG response in the context of fat loading and fenofibrate treatment. They will type 15 single nucleotide polymorphisms (SNPs) in ten candidate genes known to contribute to the response of TGs to dietary fat and fenofibrate, and create haplotypes for association studies. They will use combinatorial partitioning methods and neural networks to test association of the individual SNPs and haplotypes with response to the two environmental interventions. The identification of genetic loci that predict TG response in the presence of two disparate contexts, fat loading and fibrate therapy, may provide insights into genetic pathways (a) predisposing to hypertriglyceridemia, ultimately leading to avenues for primary prevention, and (b) predicting response to TG lowering, leading to new drug targets for hypertriglyceridemia.


Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects meeting entry criteria

Inclusion criteria:

  1. ≥18 years of age
  2. fasting TGs <1,500 mg/dl
  3. willingness to participate in the study and attend the scheduled clinic exams
  4. member of a family with at least two members in a sibship
  5. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) results within normal range
  6. creatinine ≤2.0 mg/dl

Exclusion criteria:

  1. history of liver, kidney, pancreas, or gall bladder disease or malabsorption
  2. current pregnancy
  3. insulin use
  4. use of lipid-lowering drugs (including prescription, over the counter, and nutriceuticals; volunteers taking these agents were withdrawn from them at least 4 weeks prior to the study with physician's approval)
  5. use of warfarin
  6. women of childbearing potential not using an acceptable form of contraception
  7. known hyper-sensitivity to fenofibrate
  8. history of pancreatitis within 12 months prior to enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00083369

Sponsors and Collaborators
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Donna Arnett University of Alabama at Birmingham
  More Information

No publications provided by University of Alabama at Birmingham

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University of Alabama at Birmingham Identifier: NCT00083369     History of Changes
Other Study ID Numbers: 1250, U01HL072524-05
Study First Received: May 21, 2004
Last Updated: November 16, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases processed this record on November 30, 2015